Biohit Oyj (BIOBV.HE)
EUR 2.23
(-2.19%)
EUR 2.23
(-2.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.82 Million EUR | 108.82% |
| 2022 | 862 Thousand EUR | 162.33% |
| 2021 | -1.38 Million EUR | 56.44% |
| 2020 | -3.17 Million EUR | -131.08% |
| 2019 | -1.37 Million EUR | 30.08% |
| 2018 | -1.96 Million EUR | -130.92% |
| 2017 | 6.35 Million EUR | 289.39% |
| 2016 | -3.35 Million EUR | -15.72% |
| 2015 | -2.9 Million EUR | 35.61% |
| 2014 | -4.5 Million EUR | 23.14% |
| 2013 | -5.86 Million EUR | -27.78% |
| 2012 | -4.58 Million EUR | -110.36% |
| 2011 | 44.26 Million EUR | 8630.18% |
| 2010 | 507 Thousand EUR | -57.39% |
| 2009 | 1.19 Million EUR | -9.44% |
| 2008 | 1.31 Million EUR | 386.9% |
| 2007 | -458 Thousand EUR | -220.28% |
| 2006 | -143 Thousand EUR | -333.33% |
| 2005 | -33 Thousand EUR | -113.15% |
| 2004 | 251 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 650 Thousand EUR | 0.0% |
| 2024 Q1 | 650 Thousand EUR | 62.5% |
| 2023 FY | 1.8 Million EUR | 108.82% |
| 2023 Q1 | 700 Thousand EUR | 450.0% |
| 2023 Q2 | 1.4 Million EUR | 100.0% |
| 2023 Q3 | 212.5 Thousand EUR | -84.82% |
| 2023 Q4 | 400 Thousand EUR | 88.24% |
| 2022 Q3 | -136 Thousand EUR | -109.71% |
| 2022 Q1 | 700 Thousand EUR | 333.33% |
| 2022 FY | 862 Thousand EUR | 162.33% |
| 2022 Q4 | -200 Thousand EUR | -47.06% |
| 2022 Q2 | 1.4 Million EUR | 100.0% |
| 2021 FY | -1.38 Million EUR | 56.44% |
| 2021 Q4 | -300 Thousand EUR | -100.0% |
| 2021 Q1 | -600 Thousand EUR | 40.0% |
| 2021 Q3 | -150 Thousand EUR | 88.46% |
| 2021 Q2 | -1.3 Million EUR | -116.67% |
| 2020 Q3 | -587 Thousand EUR | 70.65% |
| 2020 FY | -3.17 Million EUR | -131.08% |
| 2020 Q2 | -2 Million EUR | -100.0% |
| 2020 Q1 | -1 Million EUR | -11.11% |
| 2020 Q4 | -1 Million EUR | -70.36% |
| 2019 Q3 | -406.5 Thousand EUR | 32.25% |
| 2019 Q4 | -900 Thousand EUR | -121.4% |
| 2019 FY | -1.37 Million EUR | 30.08% |
| 2019 Q2 | -600 Thousand EUR | -100.0% |
| 2019 Q1 | -300 Thousand EUR | 43.5% |
| 2018 FY | -1.96 Million EUR | -130.92% |
| 2018 Q3 | -531 Thousand EUR | -18.0% |
| 2018 Q2 | -450 Thousand EUR | 0.0% |
| 2018 Q1 | -450 Thousand EUR | 89.8% |
| 2018 Q4 | -531 Thousand EUR | 0.0% |
| 2017 Q3 | -4.41 Million EUR | -222.58% |
| 2017 Q1 | 3.6 Million EUR | 533.21% |
| 2017 Q4 | -4.41 Million EUR | 0.0% |
| 2017 FY | 6.35 Million EUR | 289.39% |
| 2017 Q2 | 3.6 Million EUR | 0.0% |
| 2016 Q3 | -831 Thousand EUR | -10.8% |
| 2016 Q1 | -750 Thousand EUR | 46.43% |
| 2016 FY | -3.35 Million EUR | -15.72% |
| 2016 Q4 | -831 Thousand EUR | 0.0% |
| 2016 Q2 | -750 Thousand EUR | 0.0% |
| 2015 Q3 | -100 Thousand EUR | 80.0% |
| 2015 Q2 | -500 Thousand EUR | 50.0% |
| 2015 Q1 | -1 Million EUR | 16.94% |
| 2015 Q4 | -1.4 Million EUR | -1300.0% |
| 2015 FY | -2.9 Million EUR | 35.61% |
| 2014 Q1 | -1.2 Million EUR | 23.08% |
| 2014 FY | -4.5 Million EUR | 23.14% |
| 2014 Q4 | -1.2 Million EUR | -33.78% |
| 2014 Q3 | -900 Thousand EUR | 30.77% |
| 2014 Q2 | -1.3 Million EUR | -8.33% |
| 2013 Q3 | -900 Thousand EUR | 62.5% |
| 2013 Q4 | -1.56 Million EUR | -73.33% |
| 2013 Q1 | -1 Million EUR | 15.68% |
| 2013 Q2 | -2.4 Million EUR | -140.0% |
| 2013 FY | -5.86 Million EUR | -27.78% |
| 2012 FY | -4.58 Million EUR | -110.36% |
| 2012 Q3 | -1.2 Million EUR | 0.0% |
| 2012 Q2 | -1.2 Million EUR | -9.09% |
| 2012 Q4 | -1.18 Million EUR | 1.17% |
| 2012 Q1 | -1.1 Million EUR | -102.54% |
| 2011 Q4 | 43.26 Million EUR | 14320.67% |
| 2011 Q1 | 600 Thousand EUR | 252.94% |
| 2011 Q2 | 100 Thousand EUR | -83.33% |
| 2011 Q3 | 300 Thousand EUR | 200.0% |
| 2011 FY | 44.26 Million EUR | 8630.18% |
| 2010 Q2 | 500 Thousand EUR | 400.0% |
| 2010 Q3 | 300 Thousand EUR | -40.0% |
| 2010 Q1 | 100 Thousand EUR | -88.4% |
| 2010 Q4 | 170 Thousand EUR | -43.33% |
| 2010 FY | 507 Thousand EUR | -57.39% |
| 2009 Q1 | 100 Thousand EUR | 0.0% |
| 2009 FY | 1.19 Million EUR | -9.44% |
| 2009 Q4 | 862 Thousand EUR | 331.0% |
| 2009 Q3 | 200 Thousand EUR | -33.33% |
| 2009 Q2 | 300 Thousand EUR | 200.0% |
| 2008 FY | 1.31 Million EUR | 386.9% |
| 2007 FY | -458 Thousand EUR | -220.28% |
| 2006 FY | -143 Thousand EUR | -333.33% |
| 2005 FY | -33 Thousand EUR | -113.15% |
| 2004 FY | 251 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Herantis Pharma Oyj | 154.36 Thousand EUR | -1082.24% |
| Nanoform Finland Oyj | -22.47 Million EUR | 108.12% |